Physician profile
Tapaswini Trivedi
NPI 1215972021
$3,457.31
in general payments reported to CMS, 2019-2025
25 companies · $785 in 2025
The $785 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.83 · 2020: $458 · 2021: $507 · 2022: $228 · 2023: $931 · 2024: $534 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,250.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $495.10 | 2020-2024 | Jardiance |
| Pfizer INC. | $434.21 | 2020-2025 | |
| Abbvie INC. | $365.77 | 2021-2024 | Synthroid, Vraylar, Ubrelvy |
| Novo Nordisk INC | $312.60 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $297.10 | 2022-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $266.36 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $223.96 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Stryker Corporation | $141.64 | 2025 | Pangea, Variax |
| Amgen INC. | $138.70 | 2023-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $111.14 | 2023-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $97.14 | 2020-2024 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $83.29 | 2020-2021 | |
| Eisai INC. | $75.79 | 2020-2025 | |
| Idorsia Pharmaceuticals US INC | $73.78 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $53.75 | 2022-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $42.62 | 2023 | Azstarys |
| Shield Therapeutics INC | $40.08 | 2025 | |
| Dexcom, INC. | $36.95 | 2023 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $36.64 | 2023 | |
| Genentech USA, INC. | $29.48 | 2019-2020 | |
| Abbott Laboratories | $24.91 | 2023 | Freestyle Libre 3 |
| Almatica Pharma LLC | $22.39 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $21.55 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.53 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tapaswini Trivedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.